{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:27Z","timestamp":1792788207511,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:15:01Z","timestamp":1792786501000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Hemostasis"],"prefix":"10.1016","author":[{"given":"Anna","family":"Balykina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Shpakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stepan","family":"Gambaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey G.","family":"Roweth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2326-6066.CIR-14-0209","article-title":"Tumors: wounds that do not heal-redux","volume":"3","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1073\/pnas.61.1.46","article-title":"Antimetastatic effects associated with platelet reduction","volume":"61","author":"Gasic","year":"1968","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2026.09.008_bib3","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.thromres.2018.01.035","article-title":"Effects of platelets on cancer progression","volume":"164","author":"Plantureux","year":"2018","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib4","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1038\/s41467-024-47516-w","article-title":"Platelets favor the outgrowth of established metastases","volume":"15","author":"Garcia-Leon","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib5","first-page":"52","article-title":"Platelets and circulating (tumor) cells: partners in promoting metastatic cancer","volume":"32","author":"Gautam","year":"2025","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.008_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.008_bib7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.hoc.2026.09.008_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"issue":"44","key":"10.1016\/j.hoc.2026.09.008_bib9","doi-asserted-by":"crossref","first-page":"27460","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76351-4","article-title":"Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors","volume":"10","author":"Zaslavsky","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.008_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102498","article-title":"Platelets increase the expression of PD-L1 in ovarian cancer","volume":"14","author":"Cho","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.008_bib12","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1111\/jth.15478","article-title":"Platelets stimulate programmed death-ligand 1 expression by cancer cells: inhibition by anti-platelet drugs","volume":"19","author":"Asgari","year":"2021","journal-title":"J Thromb Haemostasis"},{"issue":"20","key":"10.1016\/j.hoc.2026.09.008_bib13","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1182\/bloodadvances.2021006120","article-title":"Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro","volume":"6","author":"Guo","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.008_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood.2023022928","article-title":"Procoagulant platelets promote immune evasion in triple-negative breast cancer","volume":"144","author":"Schaubaecher","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib15","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","article-title":"TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies","volume":"16","author":"Cui","year":"2025","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.008_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/HEP.0000000000000934","article-title":"Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT","volume":"81","author":"Sun","year":"2025","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.008_bib18","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.008_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.008_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cancers11030277","article-title":"Inhibition of NK reactivity against solid tumors by platelet-derived RANKL","volume":"11","author":"Clar","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.1103194","article-title":"GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity","volume":"189","author":"Placke","year":"2012","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/nop009","article-title":"TGF-Beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients","volume":"12","author":"Crane","year":"2010","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.008_bib23","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/ijms22094492","article-title":"Blood platelets as an important but underrated circulating source of TGFbeta","volume":"22","author":"Karolczak","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.008_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ygyno.2019.02.026","article-title":"Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-\u03b2 signaling pathway","volume":"153","author":"Guo","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.09.008_bib25","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.008_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1364827","article-title":"Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells","volume":"7","author":"Maurer","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.hoc.2026.09.008_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.008_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","article-title":"Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells","volume":"72","author":"Placke","year":"2012","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.008_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.hoc.2026.09.008_bib30","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3389\/fimmu.2018.02712","article-title":"Role of platelets in leukocyte recruitment and resolution of inflammation","volume":"9","author":"Rossaint","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.008_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"30","key":"10.1016\/j.hoc.2026.09.008_bib32","doi-asserted-by":"crossref","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","article-title":"Platelets guide the formation of early metastatic niches","volume":"111","author":"Labelle","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-023-02856-1","article-title":"Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment","volume":"42","author":"Chen","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.008_bib34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41416-021-01338-5","article-title":"CD8(+) T cells inhibit metastasis and CXCL4 regulates its function","volume":"125","author":"Joseph","year":"2021","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.09.008_bib35","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3390\/cancers14081947","article-title":"Platelet-derived PDGFB promotes recruitment of cancer-associated fibroblasts, deposition of extracellular matrix and tgfbeta signaling in the tumor microenvironment","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.hoc.2026.09.008_bib36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1055\/a-2523-1821","article-title":"Recent advances in immunothrombosis and thromboinflammation","volume":"125","author":"Kaiser","year":"2025","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.hoc.2026.09.008_bib37","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.3390\/cancers12123653","article-title":"Platelet-derived GARP induces peripheral regulatory T cells-potential impact on T cell suppression in patients with melanoma-associated thrombocytosis","volume":"12","author":"Zimmer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.hoc.2026.09.008_bib38","doi-asserted-by":"crossref","first-page":"eaai7911","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci Immunol"},{"issue":"525","key":"10.1016\/j.hoc.2026.09.008_bib39","doi-asserted-by":"crossref","first-page":"eaay4860","DOI":"10.1126\/scitranslmed.aay4860","article-title":"Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2","volume":"12","author":"Metelli","year":"2020","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.008_bib40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1172\/JCI121985","article-title":"Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1\/thromboxane A2","volume":"129","author":"Lucotti","year":"2019","journal-title":"J Clin Investig"},{"issue":"8060","key":"10.1016\/j.hoc.2026.09.008_bib41","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA(2) suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.008_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2024.100015","article-title":"Targeting the P-selectin\/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation","volume":"1","author":"Escopy","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.008_bib43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.immuni.2016.04.015","article-title":"PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion","volume":"44","author":"Tinoco","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.008_bib44","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1158\/2767-9764.CRC-26-0187","article-title":"Tumor-associated platelets suppress T-cell function and promote immune evasion in TNBC via the P-selectin\/P-selectin glycoprotein ligand 1 pathway","volume":"6","author":"Smith-Oliver","year":"2026","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.hoc.2026.09.008_bib45","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fonc.2020.01350","article-title":"Platelets and metastasis: new implications of an old interplay","volume":"10","author":"Lucotti","year":"2020","journal-title":"Front Oncol"},{"issue":"9826","key":"10.1016\/j.hoc.2026.09.008_bib46","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"9759","key":"10.1016\/j.hoc.2026.09.008_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.008_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults","volume":"113","author":"McNeil","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10240","key":"10.1016\/j.hoc.2026.09.008_bib49","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2026.09.008_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110350","article-title":"Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer","volume":"121","author":"Lei","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.008_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/0008-5472.CAN-24-1611","article-title":"Targeting arachidonic acid metabolism enhances immunotherapy efficacy in ARID1A-Deficient colorectal cancer","volume":"85","author":"Cui","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2026.09.008_bib52","article-title":"Does the combined use of aspirin and immunotherapy result in better outcomes in non-small cell lung cancer than immunotherapy alone?","volume":"14","author":"Aiad","year":"2022","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.008_bib53","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","article-title":"Aspirin intake and survival after breast cancer","volume":"28","author":"Holmes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.09.008_bib54","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jama.2024.4840","article-title":"Aspirin vs placebo as adjuvant therapy for breast cancer: the alliance A011502 randomized trial","volume":"331","author":"Chen","year":"2024","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.hoc.2026.09.008_bib55","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood.2019003977","article-title":"Aspirin and antiplatelet treatments in cancer","volume":"137","author":"Tao","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2026.09.008_bib56","doi-asserted-by":"crossref","first-page":"9325","DOI":"10.1073\/pnas.95.16.9325","article-title":"P-selectin deficiency attenuates tumor growth and metastasis","volume":"95","author":"Kim","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.hoc.2026.09.008_bib57","first-page":"1146","article-title":"Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3","volume":"135","author":"Mammadova-Bach","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.008_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41571-026-01122-5","article-title":"Engineering platelets as cancer therapeutics","volume":"23","author":"Chen","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.008_bib59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1021\/acsabm.2c00869","article-title":"Engineering platelets with PDL1 antibodies and iron oxide nanoparticles for postsurgical cancer immunotherapy","volume":"6","author":"Gao","year":"2023","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.hoc.2026.09.008_bib60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2019.05.008","article-title":"Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody","volume":"304","author":"Han","year":"2019","journal-title":"J Contr Release"},{"issue":"13","key":"10.1016\/j.hoc.2026.09.008_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf6854","article-title":"Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.hoc.2026.09.008_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.213796","article-title":"Engineered platelet-based immune engager for tumor post-surgery treatment","volume":"158","author":"Chen","year":"2024","journal-title":"Biomater Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:15:10Z","timestamp":1792786510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"alternative-id":["S0889858826001188"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Hemostasis","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}